JP2015522623A5 - - Google Patents

Download PDF

Info

Publication number
JP2015522623A5
JP2015522623A5 JP2015523282A JP2015523282A JP2015522623A5 JP 2015522623 A5 JP2015522623 A5 JP 2015522623A5 JP 2015523282 A JP2015523282 A JP 2015523282A JP 2015523282 A JP2015523282 A JP 2015523282A JP 2015522623 A5 JP2015522623 A5 JP 2015522623A5
Authority
JP
Japan
Prior art keywords
difluoro
methyl
hydroxy
oxopyrrolidin
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015523282A
Other languages
English (en)
Japanese (ja)
Other versions
JP6141430B2 (ja
JP2015522623A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/051261 external-priority patent/WO2014015246A1/en
Publication of JP2015522623A publication Critical patent/JP2015522623A/ja
Publication of JP2015522623A5 publication Critical patent/JP2015522623A5/ja
Application granted granted Critical
Publication of JP6141430B2 publication Critical patent/JP6141430B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015523282A 2012-07-19 2013-07-19 Ep4介在性骨関連疾患及び病態用ジフルオロラクタム組成物 Active JP6141430B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261673514P 2012-07-19 2012-07-19
US61/673,514 2012-07-19
US201361793929P 2013-03-15 2013-03-15
US61/793,929 2013-03-15
PCT/US2013/051261 WO2014015246A1 (en) 2012-07-19 2013-07-19 Difluorolactam compositions for ep4-mediated osteo related diseases and conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017091147A Division JP6766008B2 (ja) 2012-07-19 2017-05-01 Ep4介在性骨関連疾患及び病態用ジフルオロラクタム組成物

Publications (3)

Publication Number Publication Date
JP2015522623A JP2015522623A (ja) 2015-08-06
JP2015522623A5 true JP2015522623A5 (cg-RX-API-DMAC7.html) 2016-09-23
JP6141430B2 JP6141430B2 (ja) 2017-06-07

Family

ID=48916211

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015523282A Active JP6141430B2 (ja) 2012-07-19 2013-07-19 Ep4介在性骨関連疾患及び病態用ジフルオロラクタム組成物
JP2017091147A Active JP6766008B2 (ja) 2012-07-19 2017-05-01 Ep4介在性骨関連疾患及び病態用ジフルオロラクタム組成物
JP2019096736A Pending JP2019163300A (ja) 2012-07-19 2019-05-23 Ep4介在性骨関連疾患及び病態用ジフルオロラクタム組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2017091147A Active JP6766008B2 (ja) 2012-07-19 2017-05-01 Ep4介在性骨関連疾患及び病態用ジフルオロラクタム組成物
JP2019096736A Pending JP2019163300A (ja) 2012-07-19 2019-05-23 Ep4介在性骨関連疾患及び病態用ジフルオロラクタム組成物

Country Status (20)

Country Link
US (8) US9180116B2 (cg-RX-API-DMAC7.html)
EP (4) EP3175852B1 (cg-RX-API-DMAC7.html)
JP (3) JP6141430B2 (cg-RX-API-DMAC7.html)
KR (2) KR102131378B1 (cg-RX-API-DMAC7.html)
CN (4) CN104583201B (cg-RX-API-DMAC7.html)
AU (3) AU2013292356B2 (cg-RX-API-DMAC7.html)
CA (2) CA2879507A1 (cg-RX-API-DMAC7.html)
CY (1) CY1118929T1 (cg-RX-API-DMAC7.html)
DK (2) DK3175852T3 (cg-RX-API-DMAC7.html)
ES (3) ES2612921T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20170045T1 (cg-RX-API-DMAC7.html)
HU (2) HUE031190T2 (cg-RX-API-DMAC7.html)
IL (3) IL236637A (cg-RX-API-DMAC7.html)
LT (1) LT2875022T (cg-RX-API-DMAC7.html)
NZ (2) NZ704171A (cg-RX-API-DMAC7.html)
PH (1) PH12015500111A1 (cg-RX-API-DMAC7.html)
PL (1) PL2875022T3 (cg-RX-API-DMAC7.html)
PT (2) PT2875022T (cg-RX-API-DMAC7.html)
SI (1) SI2875022T1 (cg-RX-API-DMAC7.html)
WO (2) WO2014015246A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3175852B1 (en) 2012-07-19 2019-03-06 Cayman Chemical Company, Incorporated Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
EA201591793A1 (ru) 2013-03-15 2016-01-29 Кайман Кемикал Компани, Инк. Лактамные соединения в качестве селективных агонистов ep4-рецепторов для применения при лечении опосредованных ep4 заболеваний и состояний
CA2903314C (en) 2013-03-15 2023-02-14 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
KR20160048054A (ko) 2013-07-19 2016-05-03 카이맨 케미칼 컴파니 인코포레이티드 골 성장의 촉진을 위한 방법, 시스템 및 조성물
HU231033B1 (hu) 2016-03-22 2019-12-30 CHINOIN Gyógyszer és Vegyészeti Termékek Gyára Zrt. Eljárás 3-as kötést tartalmazó optikailag aktív karbonsavak, karbonsav sók és karbonsav származékok előállítására
CN106699604B (zh) * 2017-01-09 2019-01-01 四川同晟生物医药有限公司 一种沙库比曲及其中间体的制备方法
EP3446661B1 (en) 2017-08-21 2021-12-29 Cook Medical Technologies LLC Braided stent crown geometry and flare

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3975399A (en) 1974-08-06 1976-08-17 E. I. Du Pont De Nemours And Company 1,5-Disubstituted-2-pyrrolidinones, -3-pyrrolin-2-ones, and -4-pyrrolin-2-ones
ZA747723B (en) * 1974-12-11 1976-11-24 Pfizer 11-desoxy-15-substituted-omega-pentanor prostaglandins
US4154949A (en) 1974-12-11 1979-05-15 Pfizer Inc. 11-Desoxy-15-substituted-ω-pentanor prostaglandins
IT1037126B (it) 1975-03-14 1979-11-10 Erba Carlo Spa 13.4 deidro ii desossi prosta glandine
DE2517771A1 (de) 1975-04-18 1976-10-28 Schering Ag Neue prostaglandin-acetylen-analoga und verfahren zu ihrer herstellung
CA1085859A (en) 1975-06-27 1980-09-16 Wilhelm Bartmann Pyrrolidones and process for their manufacture
DE2528664A1 (de) 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
DE2619638A1 (de) 1976-05-04 1977-11-17 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
US4268522A (en) 1976-06-14 1981-05-19 Pfizer Inc. 13,14-Dihydro-15-alkenyl- and 13,14-dihydro-15-alkynyl prostaglandins and analogs thereof
US4177346A (en) 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
DE2729960A1 (de) * 1977-06-30 1979-01-18 Schering Ag Neue acetylenprostaglandine und verfahren zu ihrer herstellung
US4320136A (en) 1980-08-11 1982-03-16 E. I. Du Pont De Nemours And Company 8-Aza-16,16-difluoroprostanoids
JPS58124778A (ja) * 1982-01-20 1983-07-25 Toray Ind Inc 5,6,7−トリノル−4,8−インタ−m−フエニレンPGI↓2誘導体
US4456613A (en) 1982-12-27 1984-06-26 E. I. Du Pont De Nemours And Company 6-Keto- and 6-hydroxy-8-azaprostanoids and anti-ulcer use thereof
GB8329559D0 (en) 1983-11-04 1983-12-07 Erba Farmitalia Furyl derivatives of 16-substituted prostaglandins preparations
WO1989003387A1 (fr) 1987-10-16 1989-04-20 Toray Industries, Inc. DERIVES DE 2,5,6,7-TETRANOR-4,8-INTER-m-PHENYLENE-PGI2, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION
JPH0662599B2 (ja) * 1987-10-16 1994-08-17 東レ株式会社 2,5,6,7―テトラノル―4,8―インタ―m―フェニレンPGI2誘導体ならびにその製造法および用途
DE3835162A1 (de) * 1988-10-13 1990-04-19 Schering Ag (1s,2s,3r,5r)-2-((3s)-2-halogen-3-hydroxy-1-alken(inyl))-3-trialkylsilyloxy-7,7-(2,2-dimethyl-trimethylendioxy)-bicyclo-(3.3.0)-octan-verbindungen und verfahren zu deren herstellung
US7196054B1 (en) 1990-11-27 2007-03-27 The American National Red Cross Methods for treating wound tissue and forming a supplemented fibrin matrix
CA2093836A1 (en) 1992-04-24 1993-10-25 Wayne Gombotz Biodegradable tgf-.beta. delivery system for bone regeneration
JP3388867B2 (ja) 1994-03-31 2003-03-24 株式会社東芝 宛名領域検出装置および宛名領域検出方法
WO1996014335A1 (en) 1994-11-07 1996-05-17 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Health And Human Services Cartilage-derived morphogenetic proteins
US7517539B1 (en) 1996-10-16 2009-04-14 Etex Corporation Method of preparing a poorly crystalline calcium phosphate and methods of its use
US20020098222A1 (en) 1997-03-13 2002-07-25 John F. Wironen Bone paste
ZA984040B (en) 1997-05-15 1998-11-20 Ono Pharmaceutical Co Benzenesulfonamide compounds
US6043275A (en) 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
TWI249520B (en) 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
TWI247606B (en) 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
EA005293B1 (ru) 1999-12-22 2004-12-30 Пфайзер Продактс Инк. Производные пирролидин-2-она и их применение при лечении остеопороза
US20010056060A1 (en) 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
AU2001290250A1 (en) 2000-09-21 2002-04-02 Ono Pharmaceutical Co. Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
CN1476429A (zh) * 2000-11-27 2004-02-18 �Ʒ� 治疗骨质疏松的ep4受体选择性激动剂
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
CN1863768A (zh) * 2001-07-16 2006-11-15 霍夫曼-拉罗奇有限公司 作为ep4受体激动剂的前列腺素类似物
EP1408961B1 (en) 2001-07-16 2007-07-11 F. Hoffmann-La Roche Ag 2 pyrrolidone derivatives as prostanoid agonists
EP1409455B1 (en) * 2001-07-16 2006-01-04 F. Hoffmann-La Roche Ag Prostaglandin analogues-as ep4 receptor agonists
JP4273407B2 (ja) 2001-07-23 2009-06-03 小野薬品工業株式会社 Ep4アゴニストを有効成分とする骨量低下疾患の治療剤
US7410991B2 (en) 2001-10-23 2008-08-12 Laboratoires Serono S.A. Pyrazolidinone compounds as ligands of the prostaglandin EP2 and/or EP4 receptors
CA2466757A1 (en) * 2001-12-03 2003-06-12 Merck & Co., Inc. Method for treating ocular hypertension
WO2003047417A2 (en) 2001-12-03 2003-06-12 Merck & Co., Inc. Ep4 receptor agonist, compositions and methods thereof
TW200305425A (en) 2002-03-05 2003-11-01 Ono Pharmaceutical Co 8-Azaprostaglandin derivatives and medicament containing same as active ingredient
JP2005526080A (ja) 2002-03-18 2005-09-02 ファイザー・プロダクツ・インク 肝不全、動脈管閉鎖、緑内障又は高眼圧の治療のための選択的ep4受容体アゴニストの使用
DE60307607T2 (de) 2002-03-18 2007-08-09 Pfizer Products Inc., Groton Verwendung von selektiven ep4 rezeptor agonisten zur behandlung von krankheiten
US7326426B2 (en) 2002-03-29 2008-02-05 Ethicon, Inc. Compositions and medical devices utilizing bioabsorbable liquid polymers
US6573294B1 (en) 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
ATE487514T1 (de) 2002-06-06 2010-11-15 Merck Frosst Canada Ltd 1,5-disubstituierte pyrrolid-2-on-derivate zur verwendung als ep4 rezeptor agonisten zur behandlung von augenkrankheiten wie z.b. glaukom
US7419999B2 (en) 2002-06-10 2008-09-02 Applied Research Systems Ars Holding N.V. Gamma lactams as prostaglandin agonists and use thereof
WO2004037786A2 (en) 2002-10-25 2004-05-06 Merck Frosst Canada & Co. 2-pyrrolidones as ep4 receptor agonists
JP4582456B2 (ja) 2003-01-21 2010-11-17 小野薬品工業株式会社 8−アザプロスタグランジン誘導体およびその医薬用途
US7276531B2 (en) 2003-03-03 2007-10-02 Applied Research Systems Ars Holding N.V. G-lactam derivatives as prostaglandin agonists
US7163920B2 (en) 2003-09-30 2007-01-16 Ethicon, Inc. Peptide with osteogenic activity
MXPA06006810A (es) 2003-12-17 2006-08-23 Pfizer Prod Inc Tratamiento de afecciones que se presentan con un nivel bajo de masa osea por terapia de combinacion continua con agonistas selectivos del receptor de prostaglandina ep4 y un estrogeno.
US7169807B2 (en) 2004-04-09 2007-01-30 Allergan, Inc. 10-Hydroxy-11-dihydroprostaglandin analogs as selective EP4 agonists
US7858610B2 (en) 2004-08-10 2010-12-28 Ono Pharmaceutical Co., Ltd. Preventive and/or remedy for lower urinary tract diseases containing EP4 agonist
EP1782829A1 (en) 2004-08-10 2007-05-09 Ono Pharmaceutical Co., Ltd. Preventive and/or remedy for hyperkalemia containing ep4 agonist
US20060039949A1 (en) 2004-08-20 2006-02-23 Nycz Jeffrey H Acetabular cup with controlled release of an osteoinductive formulation
US20060057184A1 (en) 2004-09-16 2006-03-16 Nycz Jeffrey H Process to treat avascular necrosis (AVN) with osteoinductive materials
US7621963B2 (en) 2005-04-13 2009-11-24 Ebi, Llc Composite bone graft material
EP1898881B1 (en) 2005-05-27 2012-04-04 Royer Biomedical, INC. Bioresorbable polymer matrices and methods of making and using the same
KR101270876B1 (ko) 2005-09-09 2013-06-07 아그노보스 헬스케어 엘엘씨 복합 골이식 대용 시멘트 및 그로부터 제조된 물품
KR20060013354A (ko) 2005-12-09 2006-02-09 (주)코리아 본 뱅크 인산칼슘계 시멘트 첨가에 의해 개질된 탈회골 기질의 개발
US20070232660A1 (en) 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US8507545B2 (en) 2007-05-08 2013-08-13 National University Corporation, Hamamatsu University School Of Medicine Cytotoxic T cell activator comprising EP4 agonist
WO2009023193A1 (en) * 2007-08-15 2009-02-19 Cytokinetics, Incorporated Certain chemical entities, compositions, and methods
MX2010004487A (es) 2007-10-23 2010-05-05 Allergan Inc Derivados lactamicos sustituidos y sus usos para glaucoma e hipertension ocular.
US20090112332A1 (en) 2007-10-31 2009-04-30 Alexis Paul Shelokov Bone graft and bone graft substitutes with antibiotics for sustained, localized release of antibiotics for reducing postoperative surgical wound infection in spinal and other bone surgery
US8685432B2 (en) 2008-03-25 2014-04-01 University Of Utah Research Foundation Controlled release tissue graft combination biomaterials
WO2011127149A1 (en) 2010-04-06 2011-10-13 University Of Utah Research Foundation Controlled release combination biomaterials
WO2009129316A2 (en) 2008-04-15 2009-10-22 Etex Corporation Minimally invasive treatment of vertebra (mitv) using a calcium phosphate combination bone cement
WO2010011599A2 (en) 2008-07-22 2010-01-28 Osteogenex Inc. Pimethixene derivatives for promoting bone growth
WO2010025135A2 (en) 2008-08-28 2010-03-04 Osteogenex Inc. Trimeprazine and ethopropazine derivatives for promoting bone growth
US9320761B2 (en) 2008-12-18 2016-04-26 Vivex Biomedical, Inc. Bone induction system and methods
US20120270934A1 (en) 2009-07-03 2012-10-25 Concert Pharmaceuticals, Inc. Prostacyclin derivatives
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
CA2815179A1 (en) * 2010-11-10 2012-05-18 Actelion Pharmaceuticals Ltd Lactam derivatives useful as orexin receptor antagonists
JP2013542837A (ja) 2010-11-15 2013-11-28 ジンマー オーソバイオロジクス,インコーポレイティド 骨空隙充填剤
US20120283293A1 (en) 2011-05-06 2012-11-08 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving Prostaglandin E2 EP4 (PGE2 EP4) receptor activation
CA2842906A1 (en) 2011-08-02 2013-02-07 Ono Pharmaceutical Co., Ltd. Left ventricular diastolic function improving agent
US20170260173A1 (en) 2012-07-19 2017-09-14 Myometrics, Llc Difluorolactam compositions for ep4-mediated osteo related diseases and condtions
EP3175852B1 (en) 2012-07-19 2019-03-06 Cayman Chemical Company, Incorporated Difluorolactam compositions for ep4-mediated osteo related diseases and conditions
EA201591793A1 (ru) 2013-03-15 2016-01-29 Кайман Кемикал Компани, Инк. Лактамные соединения в качестве селективных агонистов ep4-рецепторов для применения при лечении опосредованных ep4 заболеваний и состояний
US9676712B2 (en) 2013-03-15 2017-06-13 Cayman Chemical Company, Inc. Lactam compounds as EP4 receptor-selective agonists for use in the treatment of EP4-mediated diseases and conditions
CA2903314C (en) * 2013-03-15 2023-02-14 Cayman Chemical Company, Inc. Methods of synthesizing a difluorolactam analog
KR20160048054A (ko) 2013-07-19 2016-05-03 카이맨 케미칼 컴파니 인코포레이티드 골 성장의 촉진을 위한 방법, 시스템 및 조성물
WO2017022045A1 (ja) 2015-08-03 2017-02-09 株式会社sizebook 携帯情報装置、寸法測定方法、および寸法測定プログラム

Similar Documents

Publication Publication Date Title
JP2015522623A5 (cg-RX-API-DMAC7.html)
US10729810B2 (en) Methods, systems, and compositions for promoting bone growth
JP2016527006A5 (cg-RX-API-DMAC7.html)
HRP20150704T1 (hr) Derivati piperidinona kao mdm2-inhibitori za lijeäśenje raka
PE20100152A1 (es) {5-[4-(6-CIANO-PIRIDIN-3-ILMETOXI)-FENIL]-[1,2,4]TRIAZOL[1,5-a]PIRIDIN-2-IL}-AMIDA DEL ACIDO CICLOPROPANCARBOXILICO Y COMPOSICIONES QUE LO COMPRENDEN
RU2010146485A (ru) Новые лиганды эстрогеновых рецепторов
MA33076B1 (fr) Utilisation d'un inhibiteur de la gamma-secretase pour le traitement du cancer
JP2016516050A5 (cg-RX-API-DMAC7.html)
HRP20170045T1 (hr) Difluorlaktamski spojevi kao selektivni agonisti ep4 receptora za uporabu za liječenje bolesti i stanja posredovanih s ep4 receptorom
RU2010107892A (ru) Производные феноксипирролидина, их применение и фармацевтические композиции, содержащие их
WO2007112000A3 (en) Treatment of pain
EP4223298A3 (en) Compositions for use in treating heavy menstrual bleeding
EP2682387A3 (en) C7-fluoro substituted tetracycline compounds
JP2014507443A5 (cg-RX-API-DMAC7.html)
US11667630B2 (en) Nitrogen-containing 6-membered cyclic compound
JP2020510661A5 (cg-RX-API-DMAC7.html)
WO2009134616A3 (en) Novel inhibitors of hepatitis c virus replication
IL205697A0 (en) 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazole-2-yl)benzenesulfon-amide derivatives, compositions comprising the same and uses thereof
JP2013507336A5 (cg-RX-API-DMAC7.html)
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
WO2006091862A3 (en) Cytokine inhibitors and their use in therapy
JP2017502063A5 (cg-RX-API-DMAC7.html)
TN2009000452A1 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
RU2004116318A (ru) Фармацевтические композиции и споосбы введения селективных агонистов ep2-рецептора
TW200603816A (en) Risedronate compositions and their methods of use